Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 13, 2005 Stephen D. Simpson	Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history.
The Motley Fool January 27, 2011 Brian Orelli	Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out.
The Motley Fool September 28, 2009 Rick Aristotle Munarriz	Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered.
The Motley Fool November 15, 2011 Dan Caplinger	Has Abbott Labs Become the Perfect Stock? For long-term investors, Abbott's continuing devotion to up its dividend -- its streak now stands at 39 years -- makes a compelling reason to hold onto your shares.
The Motley Fool October 18, 2006 Brian Lawler	Is a Buyback the Best Abbott Can Do? Abbott Labs may be out of ideas for its cash. Investors, take note.
The Motley Fool January 30, 2007 Brian Lawler	Is Bigger Better for Abbott Labs? Abbott continues its transformation into a more focused pharmaceutical powerhouse. But shares of this pharmaceutical aren't exactly cheap.
The Motley Fool October 20, 2011 Brian Orelli	Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other.
The Motley Fool July 29, 2010 Brian Orelli	Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company.
The Motley Fool January 22, 2009 Brian Orelli	Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon.
The Motley Fool June 29, 2010 Brian Orelli	Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify.
The Motley Fool August 4, 2010 Matt Koppenheffer	How Much Is Abbott Labs Worth? Is Abbott Labs' stock on sale?
The Motley Fool June 4, 2010 Jim Mueller	The Changing Face of Abbott Abbott Labs' shift in revenue sources has been a boon over the last five years.
The Motley Fool April 17, 2008 Brian Orelli	Abbott's Not Ailing Abbott produces double-digit growth; investors yawn.
The Motley Fool January 25, 2006 Stephen D. Simpson	Abbott Wins No matter what Boston Scientific does with Guidant, Abbott looks like a winner. This stock might not offer a rocket ride the way smaller biotechs and med-tech companies do, but at today's prices, at least you won't have to worry about a fiery re-entry.
The Motley Fool November 8, 2011 Brian Wilson	2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues.
The Motley Fool April 22, 2010 Brian Orelli	Abbott's Stuck in a Double-Digit Rut The company keeps cranking out solid earnings, but investors don't seem to care.
The Motley Fool April 8, 2005 Stephen D. Simpson	Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse?
BusinessWeek January 29, 2007 Michael Arndt	Abbot Labs: Diagnosis: Shrewd Moves Abbott Laboratories has announced that it is selling about two-thirds of its $4 billion diagnostics business to buy more medical products outfits to help boost overall sales and profits by at least 10% a year into the next decade.
The Motley Fool September 21, 2010 Jim Royal	3 Fat Payouts from Market Leaders Dividend payers can give your portfolio an extra line of defense.
The Motley Fool April 19, 2006 Stephen D. Simpson	Abbott Gets By Will the acquisition of Guidant's vascular business kick-start this story? Abbott has shown a pretty reliable trend of getting cheap enough to buy at least once a year. Of course, the downside to that is that the stock really hasn't gone anywhere in those seven years.
The Motley Fool July 19, 2007 Brian Lawler	Abbott on Top Abbott announces second-quarter financial results. Shares of Abbott aren't particularly expensive, considering the growth potential for its top compounds and its strong drug pipeline with compounds in development for several blockbuster indications.
The Motley Fool September 30, 2008 Selena Maranjian	Some Dividends Are Soaring Don't go thinking that dividend investing is a sleepy way to go.
The Motley Fool January 12, 2012 Brian Orelli	What to Look For From Pfizer in 2012 Leaner? Yes. Meaner? We'll see.
The Motley Fool October 21, 2010 Brian Orelli	Abbott Just Can't Get Any Love Despite meeting or beating analysts' earnings for a streak that stretches balk half a decade, Abbott Labs hasn't been able to get much love from investors.
The Motley Fool January 23, 2007 Ralph Casale	Win-Win for Abbott and GE? Abbott trades its medical diagnostics segment for cold hard cash. Will shareholders see this deal as a win-win scenario? Investors, take note.
The Motley Fool November 13, 2009 Brian Orelli	Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials.
The Motley Fool September 13, 2006	Foolish Fundamentals: Payout Ratios If you're an investor interested in dividends, you should understand the dividend payout ratio.
The Motley Fool July 17, 2008 Brian Orelli	Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release
The Motley Fool January 18, 2011 Russ Krull	Keep It or Sweep It: Johnson & Johnson? Should the company be held or sold?
The Motley Fool May 11, 2010 Brian Orelli	Abbott Makes a Push Into Selling Leftovers Abbott Labs has jumped on the established-product-division bandwagon. The company has licensed 24 products from Zydus Cadila of India and has the option to market another 40.
The Motley Fool March 10, 2010 Brian Orelli	You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't.
The Motley Fool August 26, 2010 Jordan DiPietro	Pfizer's Dividends May Not Last Forever Pfizer, which operates in the pharmaceuticals industry, currently pays a dividend of 4.5%. But what's more important than the dividend itself is Pfizer's ability to keep that that cash rolling.
The Motley Fool November 7, 2009 Dan Caplinger	These Dividend Stocks Won't Let You Down Don't put your portfolio at risk.
The Motley Fool October 15, 2008 Brian Orelli	Abbott's Stents Aren't (That) Important Abbott's shareholders shouldn't be too focused on drug-eluting stents.
The Motley Fool January 10, 2012 Rex Moore	January's Best Stocks for the Long Haul You need some corporate El Dorados in your portfolio. Here's where to find them.
The Motley Fool January 3, 2011 Rex Moore	Highest-Yielding Pharma Stocks (You Might Actually Want to Buy) How to combine high yield with low risk.
Chemistry World May 21, 2014 Phillip Broadwith	Abbott to buy Chile's CFR for $3bn The move will bolster Abbott's position in the rapidly growing markets of Latin America.
The Motley Fool September 10, 2010 Anand Chokkavelu	How Expensive Is Abbott Laboratories Stock Right Now? Abbott Laboratories has a mixed performance in hitting the ideal targets, but let's see how it compares against some competitors and industry mates.
The Motley Fool July 19, 2006 Stephen D. Simpson	No Vow of Poverty for This Abbott Abbott Labs delivers a solid quarter with broad-based growth. Investors, the stock is moderately undervalued and likely to be a worthwhile long-term holding.
The Motley Fool January 27, 2010 Brian Orelli	Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that.
The Motley Fool May 27, 2011 Rex Moore	Rising Star Buys: More Tech and Health Care Making the halves whole with II-VI, J&J, and Abbott.
The Motley Fool March 2, 2009 Dan Caplinger	7 Stocks With Dividends That Should Survive Don't get caught by a dividend cut.
The Motley Fool February 22, 2010 Rick Aristotle Munarriz	4 Dividend Stocks Showing You the Money Companies with growing yields can make you rich in more ways than the obvious.
The Motley Fool July 10, 2009 Dan Caplinger	6 Dividend Stocks You Can Depend On Lately, trying to find good dividend stocks has been like walking in a minefield. You never know when the next dividend blowup is going to do some serious damage to your portfolio. These six all have traits you want to look for.
The Motley Fool June 22, 2011 Brian Orelli	In-Licensing to the Rescue Abbott's latest deal could help shore things up.
The Motley Fool March 10, 2009 Selena Maranjian	2009: Will It Be the Worst Year Since 1958? Dividends are down, but don't write them off yet -- just proceed sensibly, and reap those profits!
The Motley Fool August 27, 2010 Jordan DiPietro	AstraZeneca's Dividends May Not Last Forever AstraZeneca's payout ratio compared to its peers is a lower percentage, which illustrates that its dividend is probably more sustainable.
The Motley Fool July 15, 2009 Brian Orelli	Less Inflammation From Abbott's Quarter Humira is headed back in the right direction.
The Motley Fool September 15, 2006 Nathan Parmelee	Dividends: Back to Basics Investors, it's back to school time. Here's your guide on the basics of dividends.
The Motley Fool April 7, 2010 Selena Maranjian	6 Companies Paying You More Standard & Poor's unsurprising news bodes well for our portfolios. Here are some of the companies that hiked their dividends in recent months.